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Objective: Costly biologic therapies have improved function and quality of life for patients 
suffering from rheumatic and inflammatory bowel diseases. In this survey, we aimed to   document 
and analyze the costs.
Methods: In 2008, the total costs of tumor necrosis factor alpha inhibitors and other biologic 
agents in Norway were registered prospectively. In addition to costs, the pattern of use in the 
four Norwegian health regions was analyzed. The expenses were calculated in Norwegian krone 
and converted into Euros.
Results: The pattern of use was similar in all four regions, indicating that national guidelines 
are followed. Whereas the cost was similar in the southeast, western, and central regions, the 
expenses per thousand inhabitants were 1.56 times higher in the northern region. This indicates 
that patients in the northern region experienced a lower threshold for access to these drugs. The 
gap in costs between trusts within northern Norway was about to be closed. The Departments 
of Rheumatology and Gastroenterology had the highest consumption rates.
Conclusion: The total cost of biologic agents was significant. Northern Norway had among the 
highest consumption rates worldwide. This can partly be explained. Further exploration calls 
for a national registry for the use of these drugs.
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Introduction
Over the last few years, patients suffering from rheumatoid arthritis (RA), ankylosing 
spondylitis (AS), psoriatic arthritis (PsA), inflammatory bowel disease (IBD), and 
skin diseases (psoriasis, pyoderma gangrenosum, Bechet’s disease) have experienced 
a   significant improvement in disease activity, development of damage, and quality of 
life due to new therapies. In parallel, health care administrators have experienced a 
significant increase in the cost of treatment due to the costly new biologic therapies 
tumor necrosis factor alpha (TNFα) inhibitors and other biologic agents. Due to 
this challenge, in 2006, the Ministry of Health and Care Services and Norwegian 
  Directorate of Health took an initiative to develop guidelines for the use of these 
drugs. In this setting, cost-effective treatment and similar access to therapy within 
the Norwegian regions were the main focus of the national health authorities. 
Furthermore, patients’ access was based on specific selection criteria published 
as national guidelines.1–4 The guidelines (Table 1) were made by national groups 
with   representatives from the Norwegian Medicines Agency; Norwegian   Knowledge 
Centre for the Health Services; Norwegian   associations for rheumatologists, der-
matologists, and   gastroenterologists; Norwegian Regional Health Authority trusts; ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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and   Norwegian Directorate of Health. According to these 
guidelines, TNFα antagonists are generally   considered as 
second- and/or third-line therapy. For example, patients 
suffering from RA are considered candidates for this 
therapy when the disease is active and they do not respond 
to disease-  modifying   antirheumatic drugs (DMARDs) 
(ie,   methotrexate),   antiflogistics, or intra-articular injec-
tion of steroids. A similar indication has been made for 
PsA and AS. Regular follow-ups are requested on a clini-
cal as well as an economic basis, with the first check-up at 
3 months. In cases of no clinical effect, TNFα antagonist 
therapy should be stopped within 3 months after initiation. 
  Furthermore, the inhibitors are considered second- or third-
line therapy in patients   suffering from Crohn’s disease (CD), 
ulcerous colitis (UC), and/or psoriatic disease.
According to the order from the Department of Health, 
the four Norwegian Regional Health Authority trusts took 
over the financing of the TNFα inhibitors and other biologic 
therapy in June 2006. Consequently, the various pharmacies 
in Norway delivering these drugs to the patients (outpatient 
setting) and/or to the hospitals have their expenses refunded 
by the trusts. In northern Norway, the Regional Health 
Authority Trust constitutes four hospital trusts and one 
pharmacy trust. Due to the fact that hospital trusts now 
have to cover the expenses, they have a common concern 
about cost-effectiveness and whether national guidelines are 
followed and good clinical practice is achieved. Malpractice 
may be costly.
During the last few years, biologic therapies have 
caused a significant rise in the cost of therapy for rheu-
matic disorders and IBD. To compensate for this situation, 
national guidelines, summaries of present knowledge, and 
recommendations for therapy have been introduced.1–5 These 
  recommendations list the first and second choice of treatment. 
In this survey, we aimed to clarify the medical cost of these 
drugs in all   Norwegian health regions and further   elucidate 
the status in the northern region. We aimed to clarify whether 
patients in the various regions had similar access to bio-
logic treatment and discuss strategies for follow-up of this 
  high-cost therapy.
Materials and methods
In the time period between January 1, 2008 and December 
31, 2008, the total cost of TNFα inhibitors and other biologic 
agents in Norway was registered prospectively by the Drug 
Procurement Cooperation (www.lisnorway.no) (DPC). This 
database has a nationwide coverage, includes all biologic 
drugs refunded by the specialist health care team, and is 
run in cooperation by the four Norwegian regional health 
authorities. The DPC’s main goal is to provide costly drugs 
to the hospital trusts at a low price by regularly announc-
ing tenders for the supply. The expenses were calculated in 
Norwegian krone (NKr) and converted into Euros (€) at a 
rate of 1€ = 9.84 NKr based on data from the National Bank 
of Norway on December 30, 2008 (www.norges-bank.no). 
The figures were calculated in absolute amounts spent and 
adjusted to the number of inhabitants in each region. The 
total costs should have been correlated to the number of 
patients in each region, but there were no national incidence 
data available.
We also accessed data from the Northern Norway 
Regional Health Authority concerning resources spent in the 
region on TNFα inhibitors and other biologic agents. Data 
from each hospital trust for 2007 and 2008 were analyzed. 
Furthermore, the accounts at the University Hospital of 
North Norway (UNN) Trust were analyzed for 10 months 
(January–October) in 2007 and 2008, respectively.
statistical analysis and authorization
Microsoft® Office Excel 2007 (Microsoft Corporation, 
Redmond, WA, USA) was used for the database and 
calculations.
Data implemented were derived from national public 
resources and aggregated data. We had no access to any individual 
patient data, and approval from the Regional Committees for 
Medical and Health Research Ethics (REK) was not necessary.
Results
The total expenditure on the TNFα inhibitors and other 
biologic agents in the four Norwegian health regions is 
shown in Figure 1 and Table 2. The cost pattern of the various 
drugs employed was similar in all regions. A somewhat 
more frequent use of etanercept in the western region was 
observed initially, but the discrepancy was minimized 
Table 1 Recommendations on the use of tumor necrosis factor 
alpha inhibitors and other biologic agents in Norway as of January 
2008 (www.lisnorway.no)
Disease First choice Second choice
Ankylosing spondylitis Etanercept Adalimumab
Rheumatoid arthritis
  First line Infliximab Etanercept
  second line Rituximab
Psoriatic disease Efalizumab Etanercept
Ulcerous colitis and 
fistulating Crohn’s disease
Infliximab
Crohn’s disease (serious) Adalimumab InfliximabClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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  during the study period. The national consumption pattern 
disclosed corresponds well with the recommendations given 
by the Drug Procurement Cooperation (www.lisnorway.no) 
(Table 1). The economic resources spent in each region are 
illustrated in Table 2. The amount was significantly higher 
(1.56 times higher) in the northern region compared with the 
other regions. Employing the consumption rates revealed in 
the southeast, western, and central regions in northern Nor-
way, the Northern Norway Regional Health Authority would 
have saved €5.5 million.
Looking at the figures from the accounts of the four 
hospital trusts within northern Norway (Figure 2), the costs 
increased by 26%–54% (mean 34.5%) from 2007 to 2008, 
indicating a harmonization of the costs within the region. 
The two southern located trusts experienced a major increase 
of costs (Helgeland Hospital Trust 54%, Nordland Hospital 
Trust 42%) compared with the others (UNN Trust 26%, 
Finnmark Hospital Trust 32%). The cost per inhabitant in 
2008 was still highest at the UNN Trust, but the gap was 
about to be closed. The figures (cost/1000 inhabitants) 
were Helgeland Hospital Trust €4002, Nordland Hospital 
Trust €4429, UNN Trust €5161, and Finnmark Hospital 
Trust €3575. These figures document minor differences in 
resources spent on TNFα inhibitors and other biologic agents 
within the northern region. Furthermore, people living “in 
the neighbourhood” of the university hospital seem to use 
these drugs more frequently than people living in other areas. 
However, this statement has to be handled with significant 
caution and should be considered within the framework 
that the UNN Trust serves as a regional university hospital 
for northern Norway and frequently takes part in research 
projects on new drugs. Inpatient therapy costs are taken care 
of by the hospital trust itself. Thus, patients referred from 
other areas of northern Norway and treated as inpatients 
will influence the balance of costs between hospitals. In a 
similar way, the Nordland Hospital Trust serves as a central 
hospital in the county of Nordland and supports the Helgeland 
Hospital Trust in its care of these patients.
Focusing on the departments at the UNN Trust, 
we   disclosed the Departments of Rheumatology and 
  Gastroenterology as the major consumers of these drugs. 
The Department of Gastroenterology spent €758,346 and 
€1,022,181 on these drugs during the first 10 months in 2007 
and 2008, respectively (an annual increase of 35%). The 
corresponding figures at the Department of Rheumatology 
were €1,602,281 and €1,861,079, indicating a 16% annual 
increase. These two departments accounted for three-quarters 
of all resources spent on TNFα inhibitors and other biologic 
agents at the UNN Trust.
Discussion
In this study, we have documented a similar pattern of use 
of various TNFα inhibitors and other biologic agents in all 
Norwegian health regions. The amount spent on these drugs 
in northern Norway was more than 1.5 times higher than in 
Table 2 The table shows the economic resources spent in 2008 
on  tumor  necrosis  factor  alpha  inhibitors  and  other  biologic 
agents within Norway and its four health regions. Costs are in 
Euros (€) and according to the 2008 pharmacy purchase price
Region Total cost (€) Inhabitantsa Cost (€)b Ratio
southeast 48,658,883 2,598,136 18,728 0.91
Western 19,862,719 967,471 20,531 0.99
Central 13,227,446 653,290 20,247 0.98
Northern 14,892,173 462,237 32,218 1.56
Norway 96,641,220 4,681,134 20,645 1.00
Notes: aNational figures as of January 1, 2007. bCost per 1000 inhabitants.
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Figure 1 The figure illustrates the cost of tumor necrosis factor alpha inhibitors and other biologic agents in 2008 in the four Norwegian health regions. Costs are according 
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the other Norwegian health regions. A subgroup analysis 
revealed that most resources were spent in rheumatology and 
gastroenterology. The latter had the fastest growth of costs.
The similar pattern of use indicated that national guide-
lines were followed.1–5 This was probably due to the fact that 
clinicians have taken an active part in the development of 
guidelines. The “obedience to guidelines” will be important 
when the new tender for the supply of biologic agents is 
announced. A common national strategy for the use of these 
drugs is of utmost importance (to achieve maximum value for 
money) when negotiating with pharmaceutical companies.
The cost-effectiveness of the biologic agents has been the 
focus of several investigators.6–14 According to Brennan et al6 
and Chen et al7 figures in rheumatology (after RA patients 
have failed at least two traditional DMARDs) have been 
calculated at around £24,000 per quality-adjusted life-year 
(QALY). The incremental cost-effectiveness ratio (ICER) for 
etanercept has been reported to be lower (£24,000/QALY) 
than the corresponding figures of adalimumab (£30,000/
QALY) and infliximab (£38,000/QALY), respectively.7 
However, these figures should be viewed with caution, as 
drug prices vary between countries and over time.
Concerning AS, cost-effectiveness analyses have led to 
diverging results.10,11 McLeod et al10 concluded that none of 
the three anti-TNFα agents (adalimumab, etanercept, inflix-
imab) was likely to be considered cost-effective. Bravo Vergel 
and Hawkins11 concluded that only etanercept (£26,361/
QALY) remained cost-effective.
The cost-effectiveness issue in the treatment of IBD has 
been the focus of at least four different groups.12–15 They all 
investigated TNFα inhibitors in the treatment of CD. We did not 
reveal any economic analysis involving UC.   Arseneau et al12 
calculated the cost/QALY between $355,450 and $377,000 
and concluded that the ICER of infliximab for   treating CD 
perianal fistulae over a 1-year period may not justify the higher 
cost. Clark et al13 compared infliximab and placebo. The 
ICER figures for chronic active CD were calculated as £6700, 
£10,400, and £84,400/QALY, depending on whether it was a 
single-dose treatment, retreatment, or maintenance treatment, 
respectively. In fistulating CD, the cost/QALY was calculated 
to be £102,000 to £123,000 and £82,000 to £96,000 for the 
most favorable retreatment assumptions. Similar figures have 
been shown by others.13–15 All these reports documented that 
maintenance treatment using   infliximab was not cost-effective 
in the case of CD. In this setting, the annual increase of total 
costs (35%) of TNFα inhibitors at the Department of Gas-
troenterology at the UNN Trust should be further analyzed. 
Most likely, this is caused by a new indication of UC, which 
together with CD is the main indication of anti-TNF in gas-
trointestinal diseases.
In northern Norway, the expenses per inhabitant were 
significantly higher than in all other regions. We did not 
reveal any increasing cost pattern from south to north within 
the northern region. Jönsson et al16 investigated international 
differences in the use of TNFα inhibitors and disclosed that 
the US had the most expensive use of these drugs, with 
Norway not far behind. Norway spent almost three times 
the average of the western European countries and Canada. 
The reason behind this has been difficult to elucidate. It has 
been suggested that a focus on the societal rather than a 
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Figure 2 The figure shows the total economic resources spent on tumor necrosis factor alpha inhibitors and other biologic agents at the four hospital trusts in northern 
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health care cost prospective may be one of the explanations.16 
The notable sequelas of uncontrolled rheumatic inflammation 
include joint damage and functional disability, which, in 
turn, cause severe economic consequences not only to the 
patients and their families but also to society. Therefore, 
pharmacoeconomic analysis should take into account all 
relevant costs.17
A possible explanation for the significant spending of these 
drugs in northern Norway may be a higher incidence of IBD 
(personal communication from Professor Jon Florholmen, 
UNN) and rheumatologic disease.18,19 A somewhat higher 
incidence of AS has been reported in northern Norway.20 
Moreover, AS is the disease with better survival on TNF 
inhibitors in comparison with RA and PsA.21 Looking at IBD, 
a difference between north and south in Europe has been 
reported, although the gap is being reduced as the incidence 
of IBD is increasing in southern Europe while it is stable in 
the north.22 However, known differences in prevalence and 
incidence cannot fully explain the different pattern of use 
within Norway. However, the clinical impression is that IBD 
is more frequent and more severe in the northern region than 
in the southern part of Norway (personal communication 
from Professor Jon Florholmen, UNN). Unpublished data 
from the Norwegian Disease-modifying Antirheumatic 
Drug Register on all disease-modifying treatment given to 
patients with RA, PsA, and AS have shown that the center 
representing north Norway (UNN) is not more liberal in 
starting treatment with TNF inhibitors than centers located 
in the southern and central regions. This is shown by the 
disease activity at onset of treatment, measured by Disease 
Activity Score 28, and by number of prior DMARDs at onset 
of TNF inhibitor treatment.
A third explanation could be that the institutions in the 
north are at the forefront of modern therapy in this setting and 
the time gap will be closed as the other regions change their 
practice. During the study period, we did not reveal any sign 
of a gap being closed, but the study period was short.
Furthermore, the distinctive characteristic of northern 
Norway may explain some of the differences in cost. This 
region constitutes half of the area of Norway but includes 
only 10% of the population. With a scattered population, cost 
of travel is significant. Keeping this fact in mind, clinicians 
may be less concerned about keeping patients off TNFα 
inhibitors because these drugs usually offer the best symp-
tom control and consequently cost of travel may be avoided. 
An alternative treatment, repeated intra-articular injections 
by corticosteroids for patients with arthritis, would imply 
considerably more traveling in north Norway.
It could be speculated that the introduction of TNFα 
inhibitors may decrease consumption of other health care 
resources and therefore should be encouraged. This was 
not observed by Juillard-Condat et al.23 However, other 
investigators have shown savings in this setting. In a Dutch 
study, Welsing et al24 concluded that the greater effectiveness 
of the TNFα inhibitors reduced medical and nonmedical 
costs compared with usual treatment by about 16% and 33%, 
respectively. Costs related to arthroplasty are significant in 
rheumatic disease. The Norwegian Orthopaedic Association 
started the Norwegian Arthroplasty Register in 1987.25 The 
register was extended to include arthroplasties in all joints in 
1994. The aim of the registry was to detect inferior implants, 
cements, and operation techniques as early as possible. 
In the future, the need for arthroplasty and possible savings, 
following the introduction of biologic agents, should be 
focused on. An increase in total cost of disease due to TNFα 
inhibitors was established in a Danish study.26 This study 
concluded that the implementation of TNFα inhibitors in 
the treatment of RA would impose additional cost per year 
on the Danish health care service in the range of €67 million 
to €188 million for a progressive scenario.
Conclusion
Northern Norway has among the highest consumption rates 
of biologic agents worldwide. This can partly be explained. 
Health care budgets in Norway have been put under high 
pressure over the last few years, and resources have been 
allocated to achieve maximum value for money. The pressure 
has been even stronger during recent months due to the 
worldwide financial crisis. In this setting, raised expenses 
on drugs (such as TNFα inhibitors) have to be covered by 
savings in other settings. There is currently a need for health 
care administrators to get an overview of the use of TNFα 
inhibitors and other biologic agents in the treatment of IBD, 
skin diseases, and rheumatic disease. This situation calls for 
a national prescription database and/or a registry that makes 
it possible to compare the estimated annual cost and number 
of patients treated, time on therapy, actual cost per patient, 
and number of patients with a prescription for a defined 
time period. The registry should also include data on disease 
activity and damage, quality of life, and working capacity and 
disability. Especially in the care of IBD, maintenance therapy 
must be avoided from a cost-effectiveness point of view.
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